Fannie Mae, Freddie Mac shares tumble after conservatorship comments
LANGHORNE, PA—Henry Scott Robert, a director at NexGel, Inc. (NASDAQ:NXGL), a small-cap healthcare company with a market capitalization of $19.44 million, sold 3,000 shares of the company’s common stock on April 10, according to a recent SEC filing. While the company posted impressive revenue growth of 112% in the last twelve months, InvestingPro analysis indicates the company is currently burning through cash. The shares were sold at a weighted average price of $2.6083, with transaction prices ranging from $2.5001 to $2.6750, resulting in a total sale value of approximately $7,824. Following this transaction, Robert holds 135,053 shares of NexGel stock. The company’s shares currently trade at $2.75, near InvestingPro’s calculated Fair Value, with a healthy current ratio of 2.07 indicating strong short-term liquidity.
The sale was conducted under a Rule 10b5-1 trading plan, a prearranged trading strategy that allows insiders to buy or sell a predetermined number of shares at a predetermined time. The shares involved in this transaction were initially purchased on the open market in September 2022 and were not part of NexGel’s recent registered direct offerings. Unlock deeper insights into insider trading patterns and 6 additional key ProTips with InvestingPro, including comprehensive analysis of the company’s financial health and future prospects.
In other recent news, Nexgel Inc. reported a significant increase in revenue for the fourth quarter of 2024, achieving $3.04 million, which exceeded the forecast of $2.98 million. This marks a 181% year-over-year growth, although the company reported a net loss of $850,000 for the quarter. The full-year revenue for 2024 was $8.69 million, reflecting a 112% increase from the previous year. Looking ahead, Nexgel has projected a minimum revenue of $2.75 million for the first quarter of 2025 and aims to achieve positive EBITDA within the year. The company is focusing on strategic product expansions and partnerships to drive further growth. Additionally, Nexgel is working on launching new products and expanding its existing product lines, including partnerships with major brands like Cintas (NASDAQ:CTAS) and Owens & Minor. Analyst firm Maxim noted that Nexgel has a strong pipeline of potential new customers and opportunities, which could support its growth trajectory.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.